If you have been reading about PTMA gene and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
DNA sequencing, one of the most fundamental technologies developed to study genetics, allows researchers to determine the sequence of nucleotides in DNA fragments. The technique of chain-termination sequencing, developed in 1977 by a team led by Frederick Sanger, is still routinely used to sequence DNA fragments. Using this technology, researchers have been able to study the molecular sequences associated with many human diseases. As sequencing has become less expensive, researchers have sequenced the genomes of many organisms using a process called genome assembly, which uses computational tools to stitch together sequences from many different fragments. These technologies were used to sequence the human genome in the Human Genome Project completed in 2003. New high-throughput sequencing technologies are dramatically lowering the cost of DNA sequencing, with many researchers hoping to bring the cost of resequencing a human genome down to a thousand dollars. Next-generation sequencing (or high-throughput sequencing) came about due to the ever-increasing demand for low-cost sequencing. These sequencing technologies allow the production of potentially millions of sequences concurrently. The large amount of sequence data available has created the subfield of genomics, research that uses computational tools to search for and analyze patterns in the full genomes of organisms. Genomics can also be considered a subfield of bioinformatics, which uses computational approaches to analyze large sets of biological data.
== Analytical methods == Chiral inversion is a very important part of designing and making drugs. Because this process can change how chiral drugs work in the body and can cause side effects that can be serious or even fatal. Traditionally, chiral inversions have been studied with NMR spectroscopy at different temperatures and chiroptical methods like polarimetry. But strong, complementary methods based on dynamic chromatography (GC, HPLC, SFC, CEC, and MEKC) and electrophoresis have been made and used to figure out how the enantiomeric composition of stereo-labile chiral compounds changes over time. Most of the time, liquid chromatographic methods are used to do enantioselective analysis of chiral drugs. When an analyte with one stereogenic center or axis is separated well, the chromatogram will show two peaks. But if the analyte is stereo-labile, the peaks tend to merge. How much coalescence there is will depend on how fast chiral inversion and enantioresolution happen. Over time, the peaks will merge into a flat area. Dynamic chromatography shows how the elution profile changes over time. This makes it useful for figuring out how pH, temperature, and solvents affect chiral inversion, which can happen on the stationary phase, in the injector, or in the detector. Multidimensional approaches have been used to improve separation and detection. Table below shows a list of common methods and experiments used to figure out chiral inversion. Any of these methods can then be used to determine chiral inversion.
In 2006, Nescafé launched the new coffee machine system "Dolce Gusto" ("sweet taste" in Italian). The system allows consumers to make various styles of coffees themselves (cappuccino, latte macchiato, espresso, lungo, etc.). Additionally, hot chocolate and cold drinks can be prepared with the machine. The machines are now sold in more than 60 countries. Unlike other Nescafé products, most Dolce Gusto beverages use roasted and ground coffee beans, instead of instant coffee. In the UK in August 2009, Nescafé unveiled a £43 million ad campaign for Nescafé, focusing on the purity of its coffee and featuring the strapline "Coffee at its brightest". Nescafé was ranked 153rd among India's most trusted brands according to the Brand Trust Report 2012, a study conducted by Trust Research Advisory. In the Brand Trust Report 2013, Nescafé was ranked 230th among India's most trusted brands and subsequently, according to the Brand Trust Report 2014, Nescafé was ranked 209th among India's most trusted brands. Nestle India has branded instant coffee as Nescafe Classic and the 70:30 mix of instant coffee and chicory as Sunrise. In Australia and New Zealand, the original instant coffee is branded "Blend 43", originally to differentiate product made locally from imported beans, from the imported version. In Pakistan, Nescafe launched an annual music show based on the same theme as of Coke Studio, named Nescafé Basement.
Like other fast-food chains, In-N-Out uses roadside billboards that direct customers to the nearest location. Billboard ads display an image of the trademarked Double-Double burger. The chain uses short radio commercials, often limited to the song "In-N-Out, In-N-Out. That's what a hamburger's all about." Television commercials, which are less common, feature the hamburger's visual appeal. In-N-Out seldom uses celebrities in ads, although John Cleese and John Goodman have voiced radio spots. In the past, the Snyders also sponsored Christmas music programming with voice-overs expressing the meaning of the holiday. In addition to commercials, In-N-Out benefits from enthusiastic fans who talk to each other. For many years, it has given customers free bumper stickers, which simply say "In-N-Out Burger" but are commonly modified to say "In-N-Out urge". The company helps devoted customers advertise its brand by selling souvenir clothing with the In-N-Out logo. Celebrity fans and free endorsements in mass media also promote the business. When Heisman Trophy winner and Ohio State quarterback Troy Smith raved about In-N-Out cheeseburgers during a press conference before the 2007 BCS National Championship Game, a senior executive said: "It does not get much better than that for us. We're kind of a small company, and we do not have any celebrity endorsers. But I think we just got the best one we could have." Huell Howser was allowed, in what is believed to be a first, to film with his television cameras inside a store for a California's Gold Special.
Sources: en.wikipedia.org
flocculation The process by which the dispersed particles in a colloid come out of suspension to aggregate into larger clumps known as floc or flake, either spontaneously or due to the addition of a clarifying agent. The term is often used to refer to a reversible aggregation in which the forces holding the particles together are weak and the colloid can be re-dispersed by agitation.
18 August – Researchers in Austria propose coupling an electron microscope to a trapped-ion quantum computer, allowing quantum information from successive electrons to be combined and potentially enabling high-resolution imaging with fewer electrons, reducing damage to sensitive samples. 19 August – Astronomers report the discovery of S301, the closest and fastest star yet observed orbiting Sagittarius A*, the supermassive black hole at the centre of the Milky Way. The star completes an orbit every 8.7 years and reaches about 25,000 km/s, or 8.5% of the speed of light, at its closest approach. Its unusually tight orbit may enable a direct measurement of Sagittarius A*'s spin within about a decade. 23 August – A review published in Global Challenges finds that no place on Earth is resilient to all of the major global catastrophic risks considered. Australia shows resilience across the widest range of scenarios, while geographic isolation, food self-sufficiency, high-quality governance and decentralisation emerge as recurring resilience factors. 26 August University College London reports that London neurosurgeons have performed the first AI-assisted brain surgery at the National Hospital for Neurology and Neurosurgery in a 48-year-old patient who was diagnosed with a brain tumour in 2024. The U.S. Food and Drug Administration approves the RAS inhibitor drug daraxonrasib as a treatment for metastatic pancreatic cancer. 30 August – NASA launches the flagship Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from the Kennedy Space Center in Florida.
=== Altered metabolism === Diabetes mellitus is a metabolic disorder, and hence the defects observed in diabetic wound healing are thought to be the result of altered protein and lipid metabolism and thereby abnormal granulation tissue formation. Increased glucose levels in the body end up in uncontrolled covalent bonding of aldose sugars to a protein or lipid without any normal glycosylation enzymes. These stable products then accumulate over the surface of cell membranes, structural proteins and circulating proteins. These products are called advanced glycation endproducts (AGEs) or Amadori products. Formation of AGEs occurs on extracellular matrix proteins with a slow turnover rate. AGEs alter the properties of matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds or cross-linking. AGE cross-linking on type I collagen and elastin results in increased stiffness. AGEs are also known to increase the synthesis of type III collagen that forms the granulation tissue. AGEs on laminin result in reduced binding to type IV collagen in the basement membrane, reduced polymer elongation, and reduced binding of heparan sulfate proteoglycan.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.